sellModerate cluster of 7
A. Sinclair Dunlop sold $445k of APLS
director at Apellis Pharmaceuticals, Inc.. 8,894 shares at an average of $49.99, traded Nov 17, 2023, filed Nov 21, 2023.
Warning score
47Value
$445k
8,894 shares
Holdings after
122,403
-7% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +17Trade size$445k at market
- 0Share of holdings soldSold 6.8% of holdings
- +15Cluster7 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001127602-23-028142, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2023 | SOpen-market sale Common Stock | -8,894 | $49.99 | $445k | 122,403 | Nov 21, 2023 |
Related signals
Other insiders at Apellis Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | APLSsell Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $8,153 368 shares | -0% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $170k 7,832 shares | -8% | |
| 49Moderate | Apellis Pharmaceuticals, Inc. | Timothy Eugene Sullivan Chief Financial Officer | $224k 10,287 shares | -10% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Nur Nicholson Chief Technical Officer | $168k 7,725 shares | -10% | |
| 59Moderate | Apellis Pharmaceuticals, Inc. | Cedric Francois Chief Executive Officer | $592k 27,192 shares | -9% | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | Pascal Deschatelets Chief Scientific Officer | $129k 5,928 shares | -1% | |
| 38Weak | Apellis Pharmaceuticals, Inc. | Mark Jeffrey DeLong Chief Business & Strat Officer | $73k 3,371 shares | -4% | |
| 36Weak | Apellis Pharmaceuticals, Inc. | James George Chopas VP/Chief Accounting Officer | $45k 2,064 shares | -4% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | Caroline Baumal Chief Medical Officer | $61k 2,797 shares | -3% | |
| 37Weak | Apellis Pharmaceuticals, Inc. | David O. Watson General Counsel | $49k 2,475 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.